Form 4: Ikena Oncology Director, David P. Bonita, Reports Stock Option Grant
SEC Form 4 Filing
Director David P. Bonita reports acquisition of stock options in Ikena Oncology, Inc.
Summary
- David P. Bonita, a director of Ikena Oncology, Inc., filed a Form 4 with the SEC.
- The report details the acquisition of 17,520 stock options with an exercise price of $1.75 on June 7, 2024.
- These options vest fully on the earlier of June 7, 2025, or the date of the next annual meeting, contingent upon continued service as a director.
- Following the transaction, Bonita directly owns 17,520 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock option grants to a director.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Key Dates
| Date | Description |
|---|---|
| 06/07/2024 | Date of stock option grant. |
| 06/07/2025 | Earliest vesting date for the stock options. |
| 06/06/2034 | Expiration date of the stock options. |
| 06/10/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.